Fortis Health. (FORTIS)

FairStock Score: 38/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Fellow shareholder, Fortis Health looks like a decent hospital business but not a bargain. The balance sheet is reasonable: debt/equity 0.34, Altman Z 4.99, free cash flow ₹644 Cr, and a Piotroski F-score of 8/9, so solvency and accounting signals are healthy. The latest quarter delivered sales of ₹2,265 Cr and net profit of ₹197 Cr. Over five years revenue compounded at 10.94%, showing some past top-line resilience. However, near-term growth is anaemic: sales growth 3.47% and profit growth -7.90%. ROE 10.76% and ROCE 11.96% do not suggest a strong moat. Promoter holding is 31.17%, and dividend yield is only 0.11%. Valuation is the real problem. At ₹929, with market cap ₹70,136 Cr, P/E 67.12, P/B 7.09, PEG 18.25, and EV/EBITDA 110.79, the price already assumes enormous future growth. Graham Number is ₹183.85 and DCF intrinsic value is ₹80.67, implying a margin of safety of -412.72%. I want to buy below intrinsic value, not at over five times Graham Number and roughly eleven times DCF value. Even though latest quarter net profit was ₹197 Cr, profit growth is -7.90%. FairStock score is 38/100, mixed. Conclusion: wait for sales and profit growth to recover, ROE/ROCE to improve, and valuation to become sane. At ₹929, there is no margin of safety. I would classify Fortis as a Slow Grower.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer